Medshine Discovery Inc.

Wuxi Biocity Biopharmaceutics Co., Ltd.

Zhuhai United Laboratories Co., Ltd.

Kpc Pharmaceuticals, Inc.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Guangzhou Joyo Pharmatech Co., Ltd.

Chinese Pla General Hospital

Novaonco Js Therapeutics Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Ocumension Therapeutics (suzhou) Co., Ltd.

Wenyuan Qian

Shuhui Chen

Jian Li

Chundao Yang

Jie Li

Zhengwei Li

Guoping Hu

Chen Zhang

Xin Li

Changqing Wei

Yonggang Liao

Yao Xiao

Jian Wang

Weiwei Mao

Guanghai Xu

Zhengying Xi

Charles Z Ding

Fei Sun

Shilan Liu

Dahai Wang

Jun Lin

Zhen Gong

Chen Li

Hongjian Wang

Qiang Guo

Zhe Cai

Kunlun He

Chunlei Liu

Ting Yao

Peng Yu

Guoqiang Dai

Lili Fan

Xuejian Zheng

Liang Fang

Liwei Mu

Yaxian Cai

Zeyu Zhang

Chaonan Liu

Liang Tan

Bao Yue

Xiaojian Gao

Yiwei Wang

The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.

Crystalline form of JAK inhibitor and application thereof

Crystalline forms of an ATR inhibitor, preparation methods therefor, and the use thereof in the preparation of a drug for treating ATR-related diseases. In particular, crystalline forms of an ATR inhibitor represented by formula (I), physicochemical and biochemical properties of the same, preparation methods for, and uses of the same, in the preparation of a drug for treating ATR-related diseases.

Crystalline form of ATR inhibitor and use thereof

Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Dimethylsulfoximine derivative

A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.

Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor

The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound and use thereof

Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.

Crystal form of Wee1 inhibitor compound and use thereof

A pyrimidopyrazolone derivative as a Wee1 inhibitor and use thereof in preparation of a medicament for treating Wee1-related diseases are described. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.

Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof

Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof. (I)

[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof

Disclosed are a diazaindole derivative as shown in formula I and the use thereof in the preparation of a drug for treating Chk1-related diseases. 

Diazaindole derivative and use thereof as CHK1 inhibitor

Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Macrocyclic compound serving as Wee1 inhibitor and applications thereof

Disclosed are a compound as an ATR inhibitor and an application in preparing a drug as an ATR inhibitor. In particular, disclosed is a compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof. 

ATR inhibitor and application thereof

The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof. 

Benzimidazole derivatives and use thereof as IDH1 inhibitors

The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. 

Heterocyclic compound as CSF-1R inhibitor and use thereof

Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases. 

Polymorph of HDAC6-selective inhibitor and application thereof

A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGIreceptor. 

Prostacyclin receptor agonist

Growing community of inventors

Shanghai, China

Wenyuan Qian